Jane Street Group, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.21 - $0.43 $3,102 - $6,353	14,775 Added 100.31%	29,505 $6,000
Q3 2023 Nov 14, 2023	SELL	$0.28 - $0.93 $6,014 - $19,977	-21,481 Reduced 59.32%	14,730 $4,000
Q2 2023 Aug 14, 2023	SELL	$0.55 - $1.26 $11,247 - $25,767	-20,450 Reduced 36.09%	36,211 $25,000
Q1 2023 May 15, 2023	BUY	$0.89 - $2.52 $38,134 - $107,976	42,848 Added 310.2%	56,661 $50,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $7.48 $14,089 - $103,321	13,813 New	13,813 $16,000
Q2 2022 Aug 16, 2022	SELL	$4.99 - $8.96 $324,764 - $583,143	-65,083 Reduced 71.31%	26,188 $165,000
Q4 2021 Feb 15, 2022	BUY	$5.12 - $8.19 $121,384 - $194,168	23,708 Added 35.09%	91,271 $474,000
Q3 2021 Nov 16, 2021	BUY	$6.68 - $9.1 $451,320 - $614,823	67,563 New	67,563 $451,000
Q1 2019 May 16, 2019	SELL	$10.31 - $14.38 $115,863 - $161,602	-11,238 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$8.63 - $12.4 $96,983 - $139,351	11,238 New	11,238 $114,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.